June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Correlation Between Fluid Status at Week 12 and Week 52 Following Intravitreal Aflibercept Injections in the VIEW Study of wAMD Patients
Author Affiliations & Notes
  • Jeffrey Marx
    Department of Ophthalmology, Lahey Clinic, Peabody, MA
  • Darius Moshfeghi
    Department of Ophthalmology, Stanford University, Palo Alto, CA
  • Seenu Hariprasad
    Department of Ophthalmology, University of Chicago, Chicago, IL
  • Jeffrey Heier
    Ophthalmic Consultants of Boston and Tufts University School of Medicine, Boston, MA
  • Footnotes
    Commercial Relationships Jeffrey Marx, Genentech (C), Parexel (C), Allergan (C); Darius Moshfeghi, None; Seenu Hariprasad, Bayer (C), Regeneron (C), Regeneron (R), Alcon (C), Alcon (R), Allergan (C), Allergan (R), OD-OS (I), Optos (C), Ocular Therapeutix (I); Jeffrey Heier, Acucela (C), Aerpio (C), Alimera (F), Allergan (C), Bayer (C), Forsight Labs (C), Fovea (F), Genentech (C), Genzyme (C), Genentech (F), Genzyme (F), Thrombogenics (C), Sequenom (C), Notal Vision (F), Novartis (F), Ophthotech (F), Ophthotech (C), Oraya (C), Paloma (F), Regeneron (F), Regeneron (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 6278. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jeffrey Marx, Darius Moshfeghi, Seenu Hariprasad, Jeffrey Heier, ; Correlation Between Fluid Status at Week 12 and Week 52 Following Intravitreal Aflibercept Injections in the VIEW Study of wAMD Patients. Invest. Ophthalmol. Vis. Sci. 2013;54(15):6278.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To determine the proportion of patients with and without fluid at week 12, one month after three initial doses of intravitreal aflibercept injections (IAI). To determine if fluid status at week 12 was associated with fluid status at week 52 and whether BCVA at week 52 was influenced by fluid status at week 12.

Methods: A total of 2457 patients with age-related macular degeneration were randomized to four treatment groups: IAI 2 mg every 4 weeks (2q4), 0.5 mg every 4 weeks (0.5q4), 2 mg every 8 weeks (2q8, after three initial monthly doses), or ranibizumab 0.5 mg every 4 weeks (Rq4). “No fluid” was defined as the absence of both cystic retinal edema and subretinal fluid. Relative risks of various events were computed using Rq4 as the control group.

Results: Compared with Rq4, the relative risks (95% CI) of having retinal/subretinal fluid at week 12 were 0.74 (0.63-0.88), 1.18 (1.03-1.36), and 0.80 (0.68-0.94) for 2q4, 0.5q4, and 2q8, respectively. In patients with fluid at week 12, the unadjusted relative risks (95% CI) of not having fluid at week 52 (compared to Rq4) were 1.34 (1.08-1.67), 1.07 (0.86-1.33), and 1.34 (1.08-1.66) for 2q4, 0.5q4, and 2q8, respectively, and the unadjusted percentages of those gaining 3 lines from week 12 to week 52 were 32%, 32%, 27%, and 30% in Rq4, 2q4, 0.5q4, and 2q8, respectively. Patients who had no fluid at week 12 were also likely to have no fluid at week 52: 80%, 85%, 79.2%, and 79% in Rq4, 2q4, 0.5q4, and 2q8, respectively. In patients who had no fluid at week 12, the unadjusted percentages of those gaining 3 lines from week 12 to week 52 were 31%, 32%, 34%, and 32% in Rq4, 2q4, 0.5q4, and 2q8, respectively. In this study, the most frequent ocular adverse events in the study population were conjunctival hemorrhage, eye pain, retinal hemorrhage, and reduced visual acuity.

Conclusions: Compared to Rq4, patients treated with IAI 2 mg were less likely to have fluid at week 12. IAI patients with fluid at week 12 were more likely than ranibizumab patients to be dry at week 52. There was no difference in BCVA between the wet and dry groups.

Keywords: 412 age-related macular degeneration • 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×